SCHIMMEL PAUL
Transaction: 05/27/2026
BUY
Change
+100,000
Price
$0.50
Filing
05/28/2026
Type
BUY
aTyr Pharma, Inc.
ATYR • Biotechnology
$0.50
▼ -0.01 (-1.23%)
Current price
EarningsLatest report: Jun 30, 2026
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$48.77M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.18Healthy liquidity · 5.3Negative growth trendWeak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 9, 2026, 12:15 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.50
Change-1.23%
Shares Out98.07M
Market Cap$48.77M
Enterprise Value$43.91M
52W Range0.40 - 6.50
Beta0.52
P/E-0.80
P/S256.69
P/B1.00
P/FCF-0.89
EV/Sales231.10
Price$0.50
Change-1.23%
Shares Out98.07M
Market Cap$48.77M
Enterprise Value$43.91M
52W Range0.40 - 6.50
Beta0.52
P/E-0.80
P/S256.69
P/B1.00
P/FCF-0.89
EV/Sales231.10
EV/EBITDA-0.71
EV/FCF-0.80
Earnings Yield-124.68%
FCF Yield-112.40%
Dividend Yield0.00%
Gross Margin-7.17%
Oper. Margin-408.56%
Profit Margin-390.09%
Debt/Eq0.18
Current Ratio5.30
Quick Ratio5.30
Target$5.13
Target Upside931.57%
Target Median$1.25
Target Range1.00 - 17.00
Volume353.52K
Avg Volume2.74M
EPS Surprise0.05
Investment DNA
How strong this company looks for long-term investors
35
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
57/100
Why this score▼
Manageable debt level · 0.18Healthy liquidity · 5.3Negative growth trendWeak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 10 analyst votes · 2026-09-05
65/100
Neutral
Bullish
3
Hold
7
Bearish
0
Price Target
2026-08-09
Low
$1.00
Mean
$5.13
Median
$1.25
High
$17.00
Insider Transactions
Recent executive and insider activity
SCHIMMEL PAUL
Transaction: 05/11/2026
BUY
Change
+50,000
Price
$0.95
Filing
05/13/2026
Type
BUY
Zaknoen Sara
Transaction: 05/11/2026
BUY
Change
+50,000
Price
$0.95
Filing
05/13/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| SCHIMMEL PAUL | BUY | +100,000 | $0.50 | 05/27/2026 | 05/28/2026 |
| SCHIMMEL PAUL | BUY | +50,000 | $0.95 | 05/11/2026 | 05/13/2026 |
| Zaknoen Sara | BUY | +50,000 | $0.95 | 05/11/2026 | 05/13/2026 |
| Lucas Svetlana | BUY | +50,000 | $0.95 | 05/11/2026 | 05/13/2026 |
| Gross Jane A | BUY | +50,000 | $0.95 | 05/11/2026 | 05/13/2026 |
| BENEVICH ERIC | BUY | +50,000 | $0.95 | 05/11/2026 | 05/13/2026 |
| Coughlin Timothy | BUY | +50,000 | $0.95 | 05/11/2026 | 05/13/2026 |
| DENYES NANCY | SELL | -1,118 | $0.98 | 02/04/2026 | 02/04/2026 |
| Broadfoot Jill Marie | SELL | -1,558 | $0.98 | 02/04/2026 | 02/04/2026 |
| Shukla Sanjay | SELL | -3,745 | $0.98 | 02/04/2026 | 02/04/2026 |
| DENYES NANCY | SELL | -2,687 | Not reported | 02/03/2026 | 02/04/2026 |
| DENYES NANCY | BUY | +2,687 | Not reported | 02/03/2026 | 02/04/2026 |
| Broadfoot Jill Marie | SELL | -3,750 | Not reported | 02/03/2026 | 02/04/2026 |
| Broadfoot Jill Marie | BUY | +3,750 | Not reported | 02/03/2026 | 02/04/2026 |
| Shukla Sanjay | SELL | -10,375 | Not reported | 02/03/2026 | 02/04/2026 |
| Shukla Sanjay | BUY | +10,375 | Not reported | 02/03/2026 | 02/04/2026 |
| DENYES NANCY | BUY | +412,500 | $0.71 | 01/09/2026 | 01/09/2026 |
| Broadfoot Jill Marie | BUY | +412,500 | $0.71 | 01/09/2026 | 01/09/2026 |
| Shukla Sanjay | BUY | +1,500,000 | $0.71 | 01/09/2026 | 01/09/2026 |
| SCHIMMEL PAUL | BUY | +317,999 | $0.94 | 10/09/2025 | 10/09/2025 |